Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2784760 | 0.87 | STAT3 (0.40) | STAT3PPARGGRM5IRAK4ROCK2 | |
| SCHEMBL67946 | 0.80 | IRAK4 (0.39) | STAT3PPARGGRM5IRAK4ALDH1A1 | |
| SCHEMBL29265661 | 0.79 | IRAK4 (0.42) | IRAK4 | |
| SCHEMBL16410312 | 0.79 | IRAK4 (0.42) | IRAK4 | |
| SCHEMBL13584896 | 0.78 | S1PR2 (0.42) | STAT3IRAK4ALDH1A1HPGDS1PR2 | |
| SCHEMBL13584897 | 0.78 | S1PR2 (0.42) | STAT3IRAK4ALDH1A1HPGDS1PR2 | |
| SCHEMBL24031283 | 0.77 | PTGS2 (0.39) | STAT3GRM5IRAK4ALDH1A1HPGD | |
| SCHEMBL17440955 | 0.77 | CTSA (0.40) | STAT3PPARGGRM5IRAK4ALDH1A1 | |
| SCHEMBL1063380 | 0.77 | ALDH1A1 (0.62) | PPARGALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL19304728 | 0.77 | RAB9A (0.40) | ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024131265-A1 | COMPOUND FOR TREATING PI3Kγ-MEDIATED DISEASES AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | STAT3 4840/4885PPARG 4668/4885GRM5 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.